Archive - 2017

Publications

Functional characterization of a novel somatic mutation of PIK3CB
Whale AD, Colman L, Lensun L, Rogers HL, Shuttleworth SJ
Signal Transduction and Targeted Therapy, 2017, in press

18 September 2017 - Press Releases

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial

Oxfordshire, UK, 18th September 2017 – Karus Therapeutics Ltd (‘Karus’), a leader in the design and development of innovative medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed with its histone deacetylase 6 (HDAC6) inhibitor, KA2507, in a Phase I clinical study. This is the Company’s second orally-active small molecule cancer therapeutic agent to enter clinical trials during the past 12 months.

Read more

04 August 2017 - Press Releases

Karus Therapeutics presenting at the CHI DoT 11th Annual Next-Generation Histone Deacetylase Inhibitors conference

Oxford, UK, 4 August 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its COO/CSO will be delivering two presentations at the CHI DoT 11th Annual Kinase Inhibitor Discovery conference, Boston, 27 and 28 September 2017.

Read more

Events

24-27 June 2017
EAS (EACR-AACR-SIC) Conference 2017, Florence, Italy

Events

13 June 2017
​Karus’s COO/CSO presenting the KA2237 program at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design Congress, Berlin

01 May 2017 - Press Releases

Karus Therapeutics presenting at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design

Oxford, UK, 1 May 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its Chief Scientific Officer will be delivering a presentation at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design Congress, Berlin, 13 June 2017.

Read more

Abstracts

Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma.
Jain N., Seghal L., Shuttleworth S.J., Samaniego F.
Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2366.

Events

9-11 January 2017
Biotech Showcase, San Franciso, USA